Home
Storia in 1 fonti
Biocon sees stronger H2 on US biosimilar launches, regulatory easing
Biocon anticipates a strong second half of FY27 due to US biosimilar launches and favorable regulatory changes enhancing growth.
Raccontata da
thehindubusinessline.com
Timeline cronologica
- ·
Biosimilars drive Biocon’s Q1 revenue growth, net profit up at ₹141 cr
Biocon's Q1 revenue rises 10% to ₹4,336 crore, driven by a 355% net profit surge from its biosimilars business.
- ·
Biocon sees stronger H2 on US biosimilar launches, regulatory easing
Biocon anticipates a strong second half of FY27 due to US biosimilar launches and favorable regulatory changes enhancing growth.